Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis.
OBJECTIVE
Treatment of multiple sclerosis patients with glatiramer acetate has been demonstrated a beneficial effect on disease activity. The objective of this prospective naturalistic study was to evaluate the impact of glatiramer acetate on fatigue and work absenteeism.


METHODS
291 treatment-naïve patients with relapsing remitting multiple sclerosis were included and treated with glatiramer acetate for twelve months. Relapse rates, disability, fatigue symptoms, days of absence from work and adverse events were monitored. Fatigue was measured with the MFIS scale and with a visual analogue scale.


RESULTS
Total MFIS scores decreased by 7.6 +/- 16.4 from 34.6 to 27.0 (p < or = 0.001). Significant reductions were observed on all three subscales of the MFIS. Fatigue symptoms, assessed using a visual analogue scale, decreased by 1.04 +/- 2.88 cm from 4.47 cm to 3.43 cm (p < or = 0.001). The proportion of patients absent from work at least once was reduced by a factor of two from 65.1% to 30.1% (p < or = 0.001). Tolerance to treatment was rated as very good or good in 78.3% of patients. Adverse effects, most frequently local injection site reactions, were reported in 15.1% of patients.


CONCLUSIONS
Treatment with glatiramer acetate was associated with a significant improvement in fatigue symptoms and a marked reduction in absence from work. Treatment was well-tolerated. Such benefits are of relevance to overall patient well-being.
Ziemssen
Tjalf
T
MS Center, Neurological University Clinic, Technical University of Dresden, Dresden, Germany. Tjalf.Ziemssen@uniklinikum-dresden.de
Hoffman
Josef
J
Apfel
Rainer
R
Kern
Simone
S
D000041:Absenteeism; D000328:Adult; D004185:Disability Evaluation; D005221:Fatigue / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005858:Germany; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy*; D019370:Observation; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate
CNS Drugs. 2003;17(4):225-34
12665396
Acta Neurol Scand. 2004 Jul;110(1):6-13
15180801
Drug Saf. 2001;24(13):979-90
11735654
Parkinsonism Relat Disord. 2007 Aug;13(6):323-32
17349813
Mult Scler. 2005 Oct;11(5):602-9
16193900
Drugs. 2004;64(12):1295-304
15200345
J Neurol Sci. 2002 Dec 15;205(1):51-8
12409184
Arch Phys Med Rehabil. 1984 Mar;65(3):135-8
6703889
Arch Neurol. 2004 Feb;61(2):201-7
14967766
J Neurol Sci. 2007 Dec 15;263(1-2):15-9
17673234
J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):34-9
16361589
J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):1045-7
15201369
J Rehabil Res Dev. 2002 Mar-Apr;39(2):211-24
12051465
J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):179-83
11796766
Curr Treat Options Neurol. 2003 Jan;5(1):35-54
12521562
Brain. 2002 Nov;125(Pt 11):2381-91
12390966
Axone. 1991 Sep;13(1):16-7, 20-2
1888670
Neurology. 2005 Apr 12;64(7):1139-43
15824337
Curr Opin Neurol. 1996 Dec;9(6):456-60
9007405
Mult Scler. 2001 Oct;7(5):340-4
11724451
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002818
17253480
Hum Brain Mapp. 2007 May;28(5):373-82
16933299
Work. 2006;27(2):143-51
16971761
Baillieres Clin Neurol. 1997 Oct;6(3):429-45
10101582
Neurology. 1983 Nov;33(11):1444-52
6685237
Ann Neurol. 2001 Jul;50(1):121-7
11456302
J Neurol. 2001 Mar;248(3):174-9
11355149
Mult Scler. 2004 Apr;10(2):165-9
15124762
Mult Scler. 2005 Apr;11(2):198-202
15794395
J Neuroimaging. 2008 Jul;18(3):314-9
18304034
Arch Neurol. 1996 Jul;53(7):642-9
8929171
Can J Neurol Sci. 1994 Feb;21(1):9-14
8180914
Mult Scler. 2002 Dec;8(6):523-6
12474995
Mult Scler. 2008 Jan;14(1):6-21
17881389